Bankruptcy for organizer of In-Awe awards

Share this article:

The Healthcare Communication & Marketing Association (HCMA)—a nonprofit group that ran courses, conferences and an awards program—filed for bankruptcy in New York.

HCMA listed debt of $182,444 and assets of $29,118. HCMA filed its voluntary petition with the bankruptcy court Dec. 17, following an October decision by HCMA's board to dissolve.

“With reduced corporate support and an increased number of unemployed members, the HCMA Board agreed that the most prudent action during these challenging times was to discontinue operations,” read a statement.

In 2007, three organizations (HMC, MMA and MHMA) joined to form the HCMA. As a national association, HCMA was designed for professionals in the healthcare industry's marketing, communications and education fields and offered career development, networking and mentoring opportunities.

Among the group's activities were the International Awards of Excellence (IN-AWE), which MMA founded in 1985 and HCMA took over to recognize healthcare-marketing creative.

The group also partnered with pharmaceutical companies, such as GlaxoSmithKline, on education and ran seminars, workshops and conferences.


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...